Mexedia S.p.A. Società Benefit (ISIN Code: IT0005450819 - Euronext Growth Paris: ALMEX) hereby informs the public that the ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

AI is accelerating the skills-first movement as employers work to keep up with the pace of technological change.

Highlights of the rese-cel clinical and translational data being presented at ACR Convergence 2025 as of the data cut-off date of September 11, 2025, and development updates include: ...

This Asian country aims to structure itself by combining the virtues of a strong state and a market economy Amid the legacy ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

(A) The Incucyte® Apoptosis Assay allows automated imaging and quantitative analysis of every well of a 96/384-well plate, ...

The convention, which will take effect after it is ratified by 40 nations, is expected to streamline international ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie ...

This study offers a valuable methodological advance by introducing a gene panel selection approach that captures combinatorial specificity to define cell identity. The findings address key limitations ...

AI refers to a machine-based system and ML refers to a set of techniques that can be used to train AI algorithms (2) so ML ...

DNA sequencing alone misses many disease dynamics. Researchers are turning to epigenomic profiling, especially the biomarker ...